BOCA vs Lazar Partners: MedTech vs Pharma PR Battle
BOCA vs Lazar Partners serves the healthcare technology and life sciences sector. Both carry genuine credibility within them. However, they approach medical communications from fundamentally different angles. Let’s say you work in MedTech or biopharma, your technology works, and your clinical data is compelling. However, turning that science into a brand story that reaches physicians, investors, payers, and the press simultaneously is a completely different kind of challenge. Understanding the BOCA vs. Lazar Partners distinction helps you identify which model best fits your organization’s stage, audience, and communication priorities. Get this right, and you choose an agency that accelerates your market position. Get it wrong, and you spend months educating a team that does not understand your regulatory environment. Let’s break both agencies down with the specificity this sector demands. BOCA Communications: The Digital PR Pioneer for MedTech and B2B High-Tech BOCA Communications is an award-winning digital PR and marketing agency headquartered in San Francisco, California. Founded in 2007, the firm serves B2B high-tech and MedTech innovators, from venture-capital-backed startups to publicly traded, global companies. BOCA integrates inbound marketing and RevOps principles into its PR offering, helping marketers achieve their goals and drive business impact. That integration of revenue operations thinking into PR strategy most clearly distinguishes BOCA from Lazar Partners at the structural level. BOCA has contributed to over $36 billion in M&A transactions and serves the high-tech and MedTech sectors. This demonstrated robust, valuable influence and deep experience for clients engaged in strategic growth and technology M&A. That track record is one of the clearest differentiators in the BOCA vs Lazar Partners debate for companies navigating transactions. Additionally, BOCA launched a proprietary professional development program, BOCA Elevate, in 2022. They trained every employee on digital PR, inbound marketing, and RevOps concepts using certified educational platforms, including HubSpot, Google Analytics, MuckRack, and LinkedIn. That investment in team-wide capability signals a firm that takes consistent service quality seriously. Key BOCA Facts BOCA Communications Areas of Strength In the BOCA vs Lazar Partners comparison, BOCA’s defining strength is its digital-first, data-integrated approach to healthcare technology PR. Where most traditional healthcare PR firms focus on earned media and analyst relationships, BOCA wraps its PR programs in inbound marketing logic. Specifically, the agency builds campaigns that simultaneously generate awareness and drive qualified traffic and revenue leads. For MedTech companies targeting hospital procurement teams, clinical decision-makers, and enterprise health system buyers, this connected approach between brand visibility and pipeline generation is practically valuable. Furthermore, BOCA’s RevOps integration means its communications programs connect to the client’s sales and marketing technology stack. Consequently, clients can track how earned media coverage contributes to pipeline movement, not just brand impression counts. The agency’s B2B high-tech capability extends well beyond MedTech into enterprise software, cloud, AI infrastructure, and cybersecurity. It made this BOCA vs. Lazar Partners comparison useful for companies at the intersection of health technology and enterprise IT. BOCA’s services include: Lazar Partners: The Pharma, Biotech, and MedTech Investor Relations Specialist Lazar Partners is a New York-based communications consultancy founded in 2001 that serves clients in the medical device, biotech, and specialty pharma industries with groundbreaking technologies and medicines. In the BOCA vs Lazar Partners context, this founding focus on life sciences rather than broad B2B tech shapes everything about how the agency operates. Founded by Fern Lazar, who previously led health and financial practices at two global PR firms, Lazar Partners built its reputation on a single defining model. The model was combining communications expertise with genuine scientific and financial fluency. The agency simultaneously employed team members trained in medicine, journalism, finance, and communications. Lazar Partners worked with four of the top six MedTech companies and several in biotech. Lazar has worked with Boston Scientific, Ethicon Endo-Surgery, Medtronic, and DePuy. In September 2019, Finn Partners acquired Lazar Partners, creating one of the largest independent health PR practices in the world. Lazar now operates as LAZAR, a Finn Partners Company, with a 2024 revenue of $5.5 million and approximately 28 employees. Lazar Partners is a health communications consultancy offering deep expertise in investor relations, public relations, marketing communications, patient-to-patient communications, medical writing, and key opinion leader engagement. In the BOCA vs Lazar Partners comparison, Lazar’s most specific differentiator is its investor relations capability combined with clinical communications depth, a combination that very few agencies offer under one roof. Key Lazar Partners Facts Lazar Partners Areas of Strength In the BOCA vs Lazar Partners comparison, Lazar’s edge lies in two capabilities. One is investor relations at a clinical-stage level, and scientific communications, including medical writing by doctoral-level staff. Lazar Partners also brings investor relations expertise to the Finn family, as well as expertise in recruiting subjects for clinical trials, patient advocacy, and the preparation and planning of scientific publications. These include three doctoral-level staffers who are experts in the latter. For a biopharma company approaching an IPO, managing a clinical data readout at a major medical meeting, or navigating FDA advisory committee communications, Lazar’s combination of IR advisory and scientific can be an advantage. This capability tips the BOCA vs Lazar Partners comparison firmly toward Lazar for clinical-stage organizations. Additionally, Lazar’s Finn Partners integration gives clients access to global reach through Finn’s network of 800-plus employees spanning the US, Europe, the Middle East, and Asia. Furthermore, Lazar’s patient advocacy and patient-to-patient engagement capabilities address a specific need for specialty pharma and rare disease companies seeking to build community awareness. Lazar’s services include: Read Also: Dukas Linden vs Cognito: Which Fintech PR Agency Wins? BOCA vs Lazar Partners: A Direct Comparison Factor BOCA Communications LAZAR, a Finn Partners Company Founded 2007, San Francisco 2001, New York City Revenue $6.4 million (2025) $5.5 million (2024) Staff 19 to 26 employees 28 employees Parent structure Independent Finn Partners Company (acquired 2019) Primary model Digital PR with RevOps integration IR-integrated specialist health PR Investor relations Not core Yes, dedicated IR practice Medical writing Not core Yes, doctoral-level scientific writers Clinical trial comms Not core Yes, patient recruitment expertise MedTech M&A support Yes,